FindTrial
Sign In

Comparison of IV and Topical tranexamic acid to reduce blood loss during transurethral resection of prostate.

A combination of intravenous and topical tranexamic acid in decreasing intraoperative haemorrhage in transurethral resection of prostate : A randomised control trial. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/058097
Enrollment
80
Registered
2023-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: IV and topical use of tranexamic acid 500mg in decreasing intraoperative haemorrhage in TURP: To evaluate the efficacy of tranexamic acid in reducing intraoperative blood loss while com

Sponsors

M S Ramaiah Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Prostate size of less than 80cc 2. ASA I-III

Exclusion criteria

Exclusion criteria: 1. History or evidence of prostate disease other than BPH 2. Treatment with any 5 Alpha reductase inhibitors within 12 months 3. Treatment with anti-platelets or anti-coagulants in perioperative period 4. Severe medical conditions like liver diseases, bleeding disorders and unstable cardiovascular problems. 5. Allergy to tranexamic acid.

Design outcomes

Primary

MeasureTime frame
Reduction of intraoperative haemorrhage in transurethral resection of prostateTimepoint: Haemoglobin measurement before & 24 hours after the surgery—

Secondary

MeasureTime frame
Reduction of intraoperative haemorrhage in transurethral resection of prostateTimepoint: Haemoglobin measurement before & 24 hours after the surgery—

Countries

India

Contacts

Public ContactDr Yatish B

M S Ramaiah medical college hospital

yatishseeni@yahoo.co.in9886197658

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026